Agendia to raise €75mn in Amsterdam IPO
This article was originally published in Scrip
Executive Summary
Dutch firm Agendia today launched its initial public offering on the NYSE Euronext stock exchange in Amsterdam, aiming to raise up to €75 million ($109.6 million). The cancer molecular diagnostics specialist plans to use the funds to expand its sales and marketing activities in the US, where it currently markets four breast cancer tests in its Symphony product line.